Ghrelin: An orexigenic and somatotrophic signal from the stomach

Nature Reviews Neuroscience

Volumn 2, Issue 8, 2001, Pages 551-560

  Inui, Akio ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PEPTIDE, (YC(CRFFNAFC)Y); AGOUTI-RELATED PEPTIDE, (YC(CRFFNAFC)Y); CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GHRELIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; LEPTIN; NEUROPEPTIDE Y; PEPTIDE; PEPTIDE FRAGMENT; PEPTIDE HORMONE;

ANIMAL; CYTOLOGY; EATING; ENERGY METABOLISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INNERVATION; METABOLISM; PHYSIOLOGY; REVIEW; SECRETION; STOMACH MUCOSA;

ANIMALS; EATING; ENERGY METABOLISM; GASTRIC MUCOSA; GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LEPTIN; NEUROPEPTIDE Y; PEPTIDE FRAGMENTS; PEPTIDE HORMONES; PEPTIDES; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 0035430665     PISSN: 14710048     EISSN: None     Source Type: Journal    
DOI: 10.1038/35086018     Document Type: Review

References (142)

1. Elmquist, J. K., Maratos-Flier, E., Saper, C. B. & Flier, J. S. Unraveling the central nervous system pathways underlying responses to leptin. Nature Neurosci. 1, 445-450 (1998).
2. Flier, J. S. & Maratos-Flier, E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 92, 437-440 (1998).
3. Woods, S. C., Seeley, R. J., Porte, D. Jr & Schwartz, M. W. Signals that regulate food intake and energy homeostasis. Science 280, 1378-1383 (1998).
4. Bray, G. A. & York, D. A. The MONA LISA hypothesis in the time of leptin. Recent Prog. Horm. Res. 53, 95-117 (1998).
5. Friedman, J. M. & Halaas, J. L. Leptin and the regulation of body weight in mammals. Nature 395, 763-770 (1998).
6. Inui, A. Feeding and body-weight regulation by hypothalamic neuropeptides - mediation of the actions of leptin. Trends Neurosci. 22, 62-67 (1999).
7. Kalra, S. P. et al. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. 20, 69-100 (1999).
8. Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J. & Baskin, D. G. Central nervous system control of food intake. Nature 404, 661-671 (2000). A recent review that provides a summary of hypothalamic effector molecules and neuronal circuits that control food intake and are regulated by leptin and insulin.
9. Inui, A. Transgenic approach to the study of body weight regulation. Pharmacol. Rev. 52, 35-61 (2000).
10. Inui, A. Transgenic study of energy homeostasis equation: implications and confounding influences. FASEB J. 14, 2158-2170 (2000).
11. Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660 (1999). Describes the isolation of ghrelin, an endogenous ligand of the growth hormone secretagogue (GHS) receptor, from stomach extracts.
12. Kojima, M., Hosoda, H., Matsuo, H. & Kangawa, K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol. Metab. 12, 118-122 (2001).
13. Frohman, L. A. & Jansson, J. O. Growth hormone-releasing hormone. Endocr. Rev. 7, 223-253 (1986).
14. Frohman, L. A., Downs, T. R. & Chomczynski, P. Regulation of growth hormone secretion. Front. Neuroendocrinol. 13, 344-405 (1992).
15. Smith, R. G. et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog. Horm. Res. 51, 261-285 (1996).
16. Frohman, L. A. et al. Secretagogues and the somatotrope: signaling and proliferation. Recent Prog. Horm. Res. 55, 269-291 (2000).
17. Momany, F. A. et al. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology 108, 31-39 (1981).
18. Bowers, C. Y. et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 106, 663-667 (1980).
19. Bowers, C. Y., Momany, F. A., Reynolds, G. A. & Hong, A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114, 1537-1545 (1984). Reports the development of potent GHSs, including growth-hormone-releasing peptide 6 (GHRP-6).
20. Bowers, C. Y., Sartor, A. A., Reynolds, D. G. & Badger, T. A. M. On the actions of the growth hormone-releasing hexapeptide, GHRP-6. Endocrinology 128, 2027-2035 (1991).
21. Korbonits, M. & Grossman, A. Growth hormone-releasing peptide and its analogues: novel stimuli to growth hormone release. Trends Endocrinol. Metab. 6, 43-49 (1995).
22. Smith, R. G. et al. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 18, 621-645 (1997). This review summarizes the GHS-GHS receptor system, its control of GH secretion and other physiological functions, as well as its clinical implications.
23. Casanueva, F. F. & Dieguez, C. Growth hormone secretagogues: physiological role and clinical utility. Trends Endocrinol. Metab. 10, 30-38 (1999).
24. Guillemin, R. et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218, 585-587 (1982).
25. Dieguez, C. & Casanueva, F. F. Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. Eur. J. Endocrinol. 142, 413-417 (2000).
26. Patchett, A. A. et al. The design and biological activities of L-163, 191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl Acad. Sci. USA 92, 7001-7005 (1995).
27. Howard, A. D. et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273, 974-977 (1996). The first demonstration of a complementary DNA that encodes the GHS receptor by the use of an expression cloning technique.
28. Dean, D. C. et al. Development of a high specific activity sulfur-35-labeted sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. J. Med. Chem. 39, 1767-1770 (1996).
29. Pong, S. S. el at. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol. Endocrinol. 10, 57-61 (1996).
30. McKee, K. K. et al. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol. Endocrinol. 11, 415-423 (1997).
31. Guan, X. M. et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res. Mol. Brain Res. 48, 23-29 (1997).
32. Chen, C., Wu, D. & Clarke, I. J. Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs. J. Endocrinol. 148, 381-386 (1996).
33. Wren, A. M. et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141, 4325-4328 (2000).
34. Takaya, K. et al. Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85, 4908-4911 (2000).
35. Date, Y. et al. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem. Biophys. Res. Commun. 275, 477-480 (2000).
36. Seoane, L. M. Ghrelin elicites a marked stimulatory effect on GH secretion in freely-moving rats. Eur. J. Endocrinol. 143, R7-9 (2000).
37. Peino, R. et al. Ghrelin-induced growth hormone secretion in humans. Eur. J. Endocrinol. 143, R11-14 (2000).
38. Bednarek, M. A. et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. 43, 4370-4376 (2000).
39. Rehfeld, J. F. The new biology of gastrointestinal hormones. Physiol. Rev. 78, 1087-1108 (1998).
40. 14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J. Biol. Chem. 275, 21995-22000 (2000).
41. Gualillo, O. et al. Ghrelin, a novel placental-derived hormone. Endocrinology 142, 788-794 (2001).
42. Tullin, S. et al. Adenosine is an agonist of the growth hormone secretagogue receptor. Endocrinology 141, 3397-3402 (2000).
43. Smith, R. G. et al. Adenosine: a partial agonist of the growth hormone secretagogue receptor. Biochem. Biophys. Res. Commun. 276, 1306-1313 (2000).
44. Tomasetto, C. et al. Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. Gastroenterology 119, 395-405 (2000). Identifies a novel cDNA from the stomach that encodes a protein named prepromotilin-related peptide (on the basis of its sequence similarity to prepromotilin).
45. Itoh, Z. Motilin and clinical application. Peptides 18, 593-608 (1997).
46. Peeters, T. L. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 105, 1886-1899 (1993).
47. Asakawa, A. et al. Ghrelin is an appetite-stimulatory signal from stomach with structual resemblance to motilin. Gastroenterology 120, 337-345 (2001). Ghrelin is the first appetite-stimulatory signal to be isolated from the stomach, and is the motilin-related peptide described in reference 44.
48. Del Rincon, J. P., Thorner, M. O. & Gaylinn, B. D. Motilin-related peptide and ghrelin: lessons from molecular techniques, peptide chemistry, and receptor biology. Gastroenterology 120, 587-588 (2001).
49. Coulie, B. J. & Miller, L. J. Identification of motilin-related peptide. Gastroenterology 120, 588-589 (2001).
50. Feighner, S. D. et al. Receptor for motilin identified in the human gastrointestinal system. Science 284, 2184-2188 (1999).
51. Thielemans, L., Depoortere, I., Assche, G. V., Bender, E. & Peeters, T. L. Demonstration of a functional motilin receptor in TE671 cells from human cerebellum. Brain Res. 895, 119-128 (2001).
52. Samson, W. K., Lumpkin, M. D., Nilaver, G. & McCann, S. M. Motilin: a novel growth hormone releasing agent. Brain Res. Bull. 12, 57-62 (1984).
53. Date, Y. et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 4255-4261 (2000).
54. Hosoda, H., Kojima, M., Matsuo, H. & Kangawa, K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. 279, 909-913 (2001).
55. Depoortere, I., De Clercq, P., Svoboda, M., Bare, L. & Peeters, T. L. Identification of motilin mRNA in the brain of man and rabbit. Conservation of polymorphism of the motilin gene across species. Peptides 10, 1497-1503 (1997).
56. Okada, K. et al. Intracerebroventricular administration of the growth hormone-releasing peptide KP-102 increases food intake in free-feeding rats. Endocrinology 137, 5155-5158 (1996).
57. Torsello, A. et al. Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Eur. J. Pharmacol. 360, 123-129 (1998).
58. Locke, W., Kirgis, H. D., Bowers, C. Y. & Abdoh, A. A. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci. 56, 1347-1352 (1995).
59. Ghigo, E. et al. Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Horm. Res. 51, 9-15 (1999).
60. Tschöp, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature 407, 908-913 (2000). Indicates an involvement of ghrelin in the regulation of energy balance by showing that ghrelin causes weight gain by reducing fat use.
61. Nakazato, M. et al. A role for ghrelin in the central regulation of feeding. Nature 409, 194-198 (2001). Ghrelin is a physiological mediator of feeding and acts through neuropeptide Y and agouti-related protein in the hypothalamus.
62. 1 receptor pathway. Diabetes 50, 227-232 (2001).
63. Hewson, A. K. & Dickson, S. L. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J. Neuroendocrinol. 12, 1047-1049 (2000).
64. Hirosue, Y. et al. Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice. Am. J. Physiol. 265, R481-486 (1993).
65. Smith, G. P. & Gibbs, J. Satiating effect of cholecystokinin. Ann. NY Acad. Sci. 713, 236-241 (1994).
66. Moran, T. H. Cholecystokinin and satiety: current perspectives. Nutrition 16, 858-865 (2000).
67. Schwartz, G. J. The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 16, 866-873 (2000).
68. Yoshida-Yoneda, E., O-Lee, T. J., Wei, J. Y., Vigna, S. R. & Tache, Y. Peripheral bombesin induces gastric vagal afferent activation in rats. Am. J. Physiol. 271, R1584-1593 (1996).
69. Kurosawa, M., Uvnas, M. K., Miyasaka, K. & Lundeberg, T. Interleukin-1 increases activity of the gastric vagal afferent nerve partly via stimulation of type A CCK receptor in anesthetized rats. J. Auton. Nerv. Syst. 12, 72-78 (1997).
70. Wang, Y. H., Tache, Y., Sheibel, A. B., Go, V. L. & Wei, J. Y. Two types of leptin-responsive gastric vagal afferent terminals: an in vitro single-unit study in rats. Am. J. Physiol. 273, R833-837 (1997).
71. Masuda, Y. et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276, 905-908 (2000).
72. Morley, J. E. Neuropeptide regulation of appetite and weight. Endocr. Rev. 8, 256-287 (1987).
73. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994).
74. Baskin, D. G., Breininger, J. F. & Schwartz, M. W. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 48, 828-833 (1999).
75. Cheung, C. C., Clifton, D. K. & Steiner, R. A. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 138, 4489-4492 (1997).
76. Campfield, L. A., Smith, F. J., Guisez, Y., Devos, R. & Burn, P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269, 546-549 (1995).
77. Schwartz, M. W., Figlewicz, D. P., Baskin, D. G., Woods, S. C. & Porte, D. Jr Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. 13, 387-414 (1992).
78. Ahima, R. S. & Flier, J. S. Leptin. Annu. Rev. Physiol. 62, 413-437 (2000).
79. Sawchenko, P. E. Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J. Comp. Neurol. 402, 435-441 (1998).
80. Elmquist, J. K., Elias, C. F. & Saper, C. B. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22, 221-232 (1999).
81. Satoh, N. et al. The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci. Lett. 224, 149-152 (1997).
82. Tang-Christensen, M., Holst, J. J., Hartmann, B. & Vrang, N. The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. Neuroreport 10, 1183-1187 (1999).
83. Dawson, R., Pelleymounter, M. A., Millard, W. J., Liu, S. & Eppler, B. Attenuation of leptin-mediated effects by monosodium glutamate-induced arcuate nucleus damage. Am. J. Physiol. 273, E202-206 (1997).
84. Tartaglia, L. A. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-1271 (1995).
85. Tartaglia, L. A. The leptin receptor. J. Biol. Chem. 272, 6093-6096 (1997).
86. Hahn, T. M., Breininger, J. F., Baskin, D. G. & Schwartz, M. W. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nature Neurosci. 1, 271-272 (1998).
87. Broberger, C., Johansen, J., Johansson, C., Schalling, M. & Hökfelt, T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc. Natl Acad. Sci. USA 95, 15043-15048 (1998).
88. Elias, C. F. et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 21, 1375-1385 (1998).
89. Ollmann, M. M. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278, 135-138 (1997).
90. Shutter, J. R. et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 11, 593-602 (1997).
91. Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J. & Cone, R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385, 165-168 (1997).
92. Stephens, T. W. et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377, 530-532 (1995).
93. Kristensen, P. et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393, 72-76 (1998).
94. Schwartz, M. W. et al. Leptin increases hypothalamic proopiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46, 2119-2123 (1997).
95. Thornton, J. E., Cheung, C. C., Clifton, D. K., & Steiner, R. A. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 138, 5063-5066 (1997).
96. Cowley, M. A. et al. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24, 155-163 (1999).
97. Kalra, S. P., Dube, M. G., Sahu, A., Phelps, C. P. & Kalra, P. S. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl Acad. Sci. USA 88, 10931-10935 (1991).
98. Dickson, S. L., Leng, G. & Robinson, I. C. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience 53, 303-306 (1993).
99. Kamegai, J., Hasegawa, O., Minami, S., Sugihara, H. & Wakabayashi, I. The growth hormone-releasing peptide KP-102 induces c-fos expression in the arcuate nucleus. Brain Res. Mol. Brain Res. 39, 153-159 (1996).
100. Willesen, M. G., Kristensen, P. & Romer, J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 70, 306-316 (1999).
101. Kamegai, J. et al. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 141, 4797-4800 (2000).
102. Torsello, A. et al. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology 72, 327-332 (2000).
103. Inui, A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol. Sci. 20, 43-46 (1999).
104. Herzog, H. Y4 receptor deletion improves fertility in ob/ob mice without affecting the obese phenotype. Proc. VIth Int. Neuropeptide Y Conf. 06 (2001).
105. Naveilhan, P. et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nature Med. 5, 1188-1193 (1999).
106. Sainsbury, A., Couzens, M., Lui, M. & Herzog, H. Critical role of Y2 receptors in body weight regulation revealed by adult-induced arcuate-specific gene deletion. Proc. VIth Int. Neuropeptide Y Conf. 014 (2001).
107. Hagan, M. M. et al. Long-term orexigenic effects of AGRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am. J. Physiol. 279, R47-52 (2000).
108. Hagan, M. M., Rushing, P. A., Benoit, S. C., Woods, S. C. & Seeley, R. J. Opioid receptor involvement in the effect of AgRP-(83-132) on food intake and food selection. Am. J. Physiol. 280, R814-821 (2001).
109. Erickson, J. C., Clegg, K. E. & Palmiter, R. D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381, 415-421 (1996).
110. 2+ in the hypothalamic arcuate nucleus neurons. Jpn. J. Physiol. 51 (in the press).
111. Cowley, M. A. et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411, 480-484 (2001).
112. Toshinai, K. et al. Upregulation of ghrelin expression in the stomach upon fasting. insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun. 281, 1220-1225 (2001).
113. Bado, A. et al. The stomach is a source of leptin. Nature 394, 790-793 (1998). Reports the presence of leptin in the stomach; this hormone is probably involved in CCK-mediated effects, including satiety.
114. Barrachina, M. D., Martinez, V., Wang, L., Wei, J. Y. & Tache, Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc. Natl Acad. Sci. USA 94, 10455-10460 (1997).
115. Matson, C. A. & Ritter, R. C. Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am. J. Physiol. 276, R1038-1045 (1999).
116. Tolle, V. et al. In vivo and in vitro effects of ghrelin/motilin-related peptide on growth hormone secretion in the rat. Neuroendocrinology 73, 54-61 (2001).
117. Minami, S., Kamegai, J., Sugihara, H., Suzuki, N. & Wakabayashi, I. Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Endocr. J. 45, S19-26 (1998).
118. Bowers, C. Y. Unnatural growth hormone-releasing peptide begets natural ghrelin. J. Clin. Endocrinol. Metab. 86, 1464-1469 (2001).
119. Korbonits, M. et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86, 881-887 (2001).
120. Chapman, I. M. et al. Stimulatbn of the growth hormone (GH)-insulin-like growth factor-I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J. Clin. Endocrinol. Metab. 81, 4249-4257 (1996).
121. Ghigo, E. et al. Biologic activities of growth hormone secretagogues in humans. Endocrine 14, 87-93 (2001).
122. Dieguez, C. & Casanueva, F. F. Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol. Metab. 6, 55-59 (1995).
123. Tschöp, M. et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707-709 (2001).
124. Levin, B. E. & Keesey, R. E. Defense of differing body weight set points in diet-induced obese and resistant rats. Am. J. Physiol. 274, R412-419 (1998).
125. Levin, B. E. Arcuate NPY neurons and energy homeostasis in diet-induced obese and resistant rats. Am. J. Physiol. 276, R382-387 (1999).
126. Kaga, T. et al. Modest overexpression of NPY in the brain leads to obesity after high sucrose feeding. Diabetes 50, 1206-1210 (2001).
127. Ziotopoulou, M., Mantzoros, C. S., Hileman, S. M. & Flier, J. S. Differental expression of hypothalamic neuropeptides in the early phase of diet-induced obesity in mice. Am. J. Physiol. 279, E833-845 (2000).
128. Flier, J. S. Clinical review 94: what's in a name? In search of leptin's physiologic role. J. Clin. Endocrinol. Metab. 83, 1407-1413 (1998).
129. Ahima, R. S. et al. Role of leptin in the neuroendocrine response to fasting. Nature 382, 250-252 (1996).
130. Bray, G. A. & York, D. A. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol. Rev. 59, 719-790 (1979).
131. Schwartz, M. W., Dallman, M. F. & Woods, S. C. Hypothalamic response to starvation: implications for the study of wasting disorders. Am. J. Physiol. 269, R949-957 (1995).
132. Inui, A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 59, 4493-4501 (1999).
133. Plata-Salaman, C. R. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 16, 1009-1012 (2000).
134. Inui, A. Cytokine and sickness behavior: implications from knockout animal models. Trends Immunol. (in the press).
135. Gayle, D., Ilyin, S. E. & Plata-Salaman, C. R. Central nervous system IL-1 beta system and neuropeptide Y mRNAs during IL-1 beta-induced anorexia in rats. Brain Res. Bull. 44, 311-317 (1997).
136. Welle, S. Growth hormone and insulin-like growth factor-I as anabolic agents. Curr. Opin. Clin. Nutr. Metab. Care 1, 257-262 (1998).
137. Van den Berghe, G. Novel insights into the neuroendocrinology of critical illness. Eur. J. Endocrinol. 143, 1-13 (2000).
138. Murphy, M. G. et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J. Clin. Endocrinol. Metab. 83, 320-325 (1998).
139. Van den Berghe, G. et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J. Clin. Endocrinol. Metab. 83, 309-319 (1998).
140. Hansen, B. S. et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur. J. Endocrinol. 141, 180-189 (1999).
141. Leibowitz, S. F. Brain peptides and obesity: pharmacologic treatment. Obes. Res. 3, 573S-589S (1995).
142. Levine, A. S. & Billington, C. J. Obesity: progress through genetic manipulation. Curr. Biol. 8, R251-252 (1998).